Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Assets Average (2023 - 2025)

Silence Therapeutics (SLN) has disclosed Assets Average for 3 consecutive years, with $139.1 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 12.8% to $139.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.1 million through Dec 2025, down 12.8% year-over-year, with the annual reading at $167.0 million for FY2025, 3.72% up from the prior year.
  • Assets Average hit $139.1 million in Q4 2025 for Silence Therapeutics, down from $156.0 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $457.1 million in Q4 2023 to a low of $139.1 million in Q4 2025.
  • Historically, Assets Average has averaged $244.1 million across 3 years, with a median of $179.5 million in 2024.
  • Biggest five-year swings in Assets Average: crashed 65.1% in 2024 and later decreased 12.8% in 2025.
  • Year by year, Assets Average stood at $457.1 million in 2023, then plummeted by 65.1% to $159.5 million in 2024, then fell by 12.8% to $139.1 million in 2025.
  • Business Quant data shows Assets Average for SLN at $139.1 million in Q4 2025, $156.0 million in Q3 2025, and $175.3 million in Q2 2025.